NCT00698763

Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables

Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables and Cerebrovascular Reactivity in Patients With Recent Stroke or TIA.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Orion Corporation, Orion Pharma · Industry
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to explore the safety of low doses of oral levosimendan in patients with recent history of an ischaemic cerebrovascular event (stroke or TIA). The main focus will be on the evaluation of proarrhythmic potential of the different dose regimens.

Detailed description

This is a prospective, multicentre, phase II, randomized, double-blind, placebo-controlled 2-arm parallel group study with 5 escalating dose-levels of oral levosimendan, each given for 13-18 days. The study population will be randomly allocated either to the levosimendan group or to the placebo group. The double-blind phase with either placebo or levosimendan is preceded by a 13-day long single-blind treatment with placebo (placebo run-in). The study consists of 9 visits (screening visit, 7 visits during the treatment period and an end-of-study visit). Each subject will be on study treatment (including placebo run-in) for 78-108 days and the duration of the study for each subject, including the screening and the end of study visit, is approximately 17 weeks.

Conditions

• Transient Ischemic Attack
• Stroke

Interventions

Type	Name	Description
DRUG	Levosimendan	from 0.125 mg to 2 mg in escalating doses
DRUG	Placebo	Placebo capsules are identical in appearance to active capsules

Timeline

• Start date: 2008-08-01
• Primary completion: 2009-04-01
• Completion: 2009-09-01
• First posted: 2008-06-17
• Last updated: 2009-11-25

Locations

7 sites across 4 countries: Finland, Germany, Hungary, Sweden